B Group Inc. Takes $3.89 Million Position in Aura Biosciences, Inc. (NASDAQ:AURA)

B Group Inc. bought a new stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 472,576 shares of the company's stock, valued at approximately $3,885,000. Aura Biosciences makes up about 2.4% of B Group Inc.'s investment portfolio, making the stock its 8th biggest position. B Group Inc. owned approximately 0.95% of Aura Biosciences as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in AURA. State Street Corp boosted its position in Aura Biosciences by 3.7% during the third quarter. State Street Corp now owns 754,803 shares of the company's stock worth $6,725,000 after purchasing an additional 26,841 shares in the last quarter. Barclays PLC raised its stake in shares of Aura Biosciences by 256.5% during the 3rd quarter. Barclays PLC now owns 61,010 shares of the company's stock worth $544,000 after buying an additional 43,897 shares during the period. Geode Capital Management LLC lifted its position in shares of Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock valued at $8,990,000 after buying an additional 39,379 shares in the last quarter. Franklin Resources Inc. grew its stake in Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company's stock valued at $15,571,000 after acquiring an additional 215,597 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in Aura Biosciences by 107.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company's stock worth $477,000 after acquiring an additional 27,718 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Trading Down 2.5 %

AURA stock traded down $0.14 during mid-day trading on Friday, reaching $5.38. The company's stock had a trading volume of 244,554 shares, compared to its average volume of 201,598. The stock has a market cap of $270.21 million, a PE ratio of -3.11 and a beta of 0.43. The company's 50 day moving average is $6.52 and its two-hundred day moving average is $8.08. Aura Biosciences, Inc. has a fifty-two week low of $4.84 and a fifty-two week high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.09). On average, analysts forecast that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on AURA shares. HC Wainwright set a $25.00 target price on shares of Aura Biosciences in a research report on Tuesday, March 25th. JMP Securities set a $19.00 price objective on Aura Biosciences in a report on Wednesday, March 26th. Citigroup reiterated an "outperform" rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. Finally, Lifesci Capital upgraded Aura Biosciences to a "strong-buy" rating in a research report on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Aura Biosciences presently has an average rating of "Buy" and a consensus target price of $22.75.

Insider Activity

In other Aura Biosciences news, insider Conor Kilroy sold 7,162 shares of Aura Biosciences stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $5.49, for a total value of $39,319.38. Following the sale, the insider now owns 179,313 shares in the company, valued at $984,428.37. The trade was a 3.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 14,148 shares of company stock valued at $91,434 in the last 90 days. Company insiders own 5.40% of the company's stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.